E&L Storyboards for Inspections and HA Meetings


Published on 02/12/2025

E&L Storyboards for Inspections and HA Meetings

Introduction to Extractables and Leachables (E&L)

In the pharmaceutical industry, the safety and efficacy of drug formulations are paramount. As these formulations come into contact with various materials during their lifecycle, understanding the potential risks posed by extractables and leachables (E&L) is crucial. Extractables are the substances that can be extracted from packaging or delivery systems under controlled conditions, while leachables are those that migrate into the drug product under normal storage conditions.

E&L risk assessment is a critical component of product development and compliance with regulatory guidelines, including the FDA, EMA, and MHRA. It involves considering how these substances might affect the quality, safety, and efficacy of pharmaceutical products. E&L studies inform the development of risk management plans that align with the guidelines set forth in EU GMP Annex 1 and industry best practices such as the PQRI guideline.

Regulatory Framework for E&L in Pharmaceuticals

Compliance with regulatory requirements surrounding E&L is essential for ensuring that pharmaceutical products meet the necessary safety and quality standards. In the US, the FDA requires that all materials intended to come into contact with drug products undergo thorough evaluation for extractables and leachables to meet the standards laid out in the Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics. Similarly, the EMA enforces stringent guidelines under the EU GMP Annex 1, which mandates rigorous E&L evaluations for pharmaceutical packaging systems.

The analytical evaluation threshold (AET) and dose-based threshold (DBT) are critical concepts in conducting E&L assessments. The AET is used to determine the minimum concentration of leachables that may raise concern regarding safety or efficacy, while the DBT refers to the acceptable limits of leachables based on the dosage administered to patients.

Additionally, regulatory agencies emphasize the importance of maintaining container closure integrity (CCI) throughout the product life cycle. This is vital not only for ensuring the sterility of products but also for preventing contamination that may arise from leachable substances.

Step 1: Implementing E&L Risk Assessment

The foundation of a comprehensive E&L strategy begins with risk assessment. Here’s how to develop a systematic E&L risk assessment process:

  1. Identify Materials: Start by identifying all components that may interact with the drug product, including containers, closures, valves, and those used in single-use systems validation.
  2. Review Material Data: Collect and review data from manufacturers regarding the materials used in packaging systems. Assess certificate of analyses (CoA) to understand the composition of materials and potential extractables.
  3. Evaluate Exposure Levels: Calculate exposure levels of the extracted substances. This involves determining the maximum potential leachable from the containers or systems under normal conditions.

Step 2: Performing AET and DBT Calculations

The analytical evaluation threshold (AET) and dose-based threshold (DBT) calculations are necessary to establish safe exposure levels for patients. Here’s a step-by-step process to perform AET and DBT calculations:

  1. Gather Toxicological Data: Collect toxicological data from recognized databases and literature sources. This may include Guidance for Industry documents and information from organizations like WHO.
  2. Calculate AET: The AET is calculated based on the acceptable daily exposure (ADE) of the leachable. Use the following formula:

    AET = ADE / (Safety Factor × Daily Dose)

    where the Safety Factor is often 100 or greater, depending on the toxicological concern.

  3. Determine DBT: Similarly, the DBT can be calculated using a dose-based approach:

    DBT = AED x DBT Value

    where AED is defined as the maximum dose administered over a defined period.

Step 3: Conducting E&L Studies

Once the risk assessment and threshold calculations have been established, E&L studies must be conducted to gather empirical evidence on leachables and their potential impact on drug product quality.

  1. Design the Study Protocol: Develop a clear study protocol that outlines the duration, conditions, and methods of extraction. Consider accelerated extraction studies to simulate real-time scenarios.
  2. Use Appropriate Methodologies: Employ validated analytical methods such as GC-MS, HPLC, or LC-MS to quantitatively measure any leachables present in the drug product.
  3. Data Analysis: Analyze the results and compare them against established AET and DBT values. Employ risk analysis techniques as necessary to interpret the results. Evaluate variability based on testing conditions, material sources, and potential interferences.

Step 4: Documentation and Reporting

Documentation is vital in the pharmaceutical industry, especially during inspections and regulatory submissions. The following aspects should be documented and reported:

  1. Study Report: Prepare and maintain comprehensive study reports detailing all methodologies, analytical conditions, and results. Ensure that the reports contain sufficient detail to allow for reproducibility.
  2. Risk Management Documentation: Document the risk assessment and justification regarding the acceptable levels of extractables and leachables as per regulatory expectations.
  3. Inspection Readiness: Have readily available E&L reports, analytical data, and risk assessments for any upcoming inspections by regulatory agencies such as the FDA or EMA.

Step 5: Container Closure Integrity (CCI) Testing

Container closure integrity is an essential aspect of ensuring the sterility and safety of pharmaceutical products. In conjunction with E&L evaluations, CCI testing helps to validate that no microbial contamination can occur through the packaging system.

  1. Explore CCI Testing Methods: Utilize methods such as vacuum decay, pressure decay, or dye penetration techniques to assess the integrity of container closures. Each method has its specific use cases and limitations.
  2. Establish Acceptance Criteria: Define clear acceptance criteria based on regulatory guidelines. Ensure that all testing is compliant with the USP CCI standards and relevant industry practices.
  3. Document CCI Results: Maintain a systematic record of CCI testing results and link them back to E&L studies, where appropriate. This holistic documentation supports underlying product safety claims and aids in regulatory submissions.

Conclusion

The successful management of extractables and leachables is integral to pharmaceutical product integrity and patient safety. By following a systematic approach that encompasses risk assessment, threshold calculations, E&L studies, and container closure integrity testing, manufacturers can ensure compliance with cGMP standards while facilitating robust interactions during health authority meetings and inspections.

In today’s complex regulatory landscape, staying informed about the latest changes in guidance and industry practices is crucial. The ongoing collaboration between pharmaceutical companies and regulatory authorities will continue to advance methodologies surrounding extractables and leachables, ultimately enhancing the safety and efficacy of drug products intended for patient use.